Literature DB >> 17968461

Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.

Tai Young Ahn1, Sung Won Lee, Sae-Woong Kim, Dae Yul Yang, Nam Cheol Park, Kweon-Sik Min, Kwangsung Park, Jae-Seung Paick, Yulia Dyachkova, Trisha Dwight, Myung-Sea Luke Lee.   

Abstract

AIM: To evaluate patient preferences for sildenafil citrate or tadalafil (PDE-5 inhibitors available for the treatment of erectile dysfunction [ED]) and assess potential reasons for these preferences.
METHODS: This open-label study was conducted on Korean men taking sildenafil, at least 6 weeks prior to study entry, for ED. Following screening, patients continued sildenafil treatment for 4 weeks, then after a 1-week washout period, switched to tadalafil for 8 weeks. Patients then continued with their treatment of choice during an extension phase. Psychosocial factors (time concern, spontaneity, sexual self-confidence) were evaluated using Psychological and Interpersonal Relationship Scales (PAIRS), while timing of dose to sexual attempt patterns were assessed from patient diaries.
RESULTS: The present study enrolled 160 Korean men (mean age 55 years) with prior median sildenafil use of 585 days. During the extension phase, 73.7% of patients elected to take tadalafil, whereas 26.3% chose sildenafil (P < 0.001). After switching from sildenafil to tadalafil, mean PAIRS time concern scores decreased from 2.54 to 2.42 (P = 0.002), with no statistically significant differences observed between the sildenafil and tadalafil assessment phases in sexual spontaneity and self-confidence scores. Sexual attempts made > 4 h to =/< 36 h post-dose occurred in 4.5% of patients during the sildenafil assessment phase compared with 17.5% during the tadalafil assessment phase.
CONCLUSION: After experiencing both sildenafil and tadalafil, the majority of patients exhibited a preference for tadalafil. This preference might be influenced by psychosocial factors, such as decreased time concerns, and a broader window of opportunity available for sexual activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17968461     DOI: 10.1111/j.1745-7262.2007.00319.x

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  5 in total

1.  Effect of tadalafil in chronic renal failure rabbits: relevance to erectile dysfunction.

Authors:  Meng-yuan Zhang; Qiang Fu; Wei Bian
Journal:  J Zhejiang Univ Sci B       Date:  2011-06       Impact factor: 3.066

2.  Evolution of Phosphodiesterase-5 Inhibitors.

Authors:  Du Geon Moon
Journal:  World J Mens Health       Date:  2015-12-23       Impact factor: 5.400

3.  Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis.

Authors:  Ying-Lu Guo; Vijay P Viswanathan; Han-Sun Chiang; Hyung Ki Choi; Andrew Wai Chun Yip; Wei Shen; Vladimir Kopernicky
Journal:  Asian J Androl       Date:  2009-04-20       Impact factor: 3.285

4.  Erectile dysfunction - an update of current practice and future strategies.

Authors:  Jas Kalsi; Asif Muneer
Journal:  J Clin Urol       Date:  2013-07

Review 5.  Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.

Authors:  Binbin Gong; Ming Ma; Wenjie Xie; Xiaorong Yang; Yongming Huang; Ting Sun; Yanping Luo; Jiao Huang
Journal:  Int Urol Nephrol       Date:  2017-07-24       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.